ACADIA PHARMACEUTICALS INC (ACAD) — SEC Filings

Latest SEC filings for ACADIA PHARMACEUTICALS INC (ACAD), explained in plain English.

Sentiment Overview: 2 bullish, 31 neutral, 1 mixed

Recent Filings (34)

• Acadia Pharma's Net Income Soars 42% on Strong Product Sales — 10-Q · 2025-11-06T00:00:00.000Z [bullish] Risk: medium
  ACADIA PHARMACEUTICALS INC. reported a significant increase in net income for the nine months ended September 30, 2025, reaching $117.432 million, up from $82.7
• 8-K Filing — 8-K · 2025-11-05T00:00:00.000Z [neutral]
• Acadia Pharma Elects New Directors, Adjusts CMO Compensation — 8-K · 2025-11-03T00:00:00.000Z [neutral] Risk: low
  Acadia Pharmaceuticals Inc. announced on October 28, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two n
• Acadia Narrows Losses on Strong DAYBUE Sales, Revenue Jumps 15% — 10-Q · 2025-08-07T00:00:00.000Z [mixed] Risk: medium
  ACADIA PHARMACEUTICALS INC reported a significant increase in revenue for the three months ended June 30, 2025, reaching $148.9 million, up from $129.2 million
• Acadia Pharmaceuticals Files 8-K on Financials — 8-K · 2025-08-06T00:00:00.000Z [neutral] Risk: low
  Acadia Pharmaceuticals Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition, and including financial statements a
• ACADIA Pharmaceuticals Files 8-K Report — 8-K · 2025-06-10T00:00:00.000Z [neutral] Risk: low
  On June 9, 2025, ACADIA Pharmaceuticals Inc. filed an 8-K report to disclose other events. The filing does not contain specific details regarding material event
• Acadia Pharmaceuticals Files 8-K on Shareholder Votes — 8-K · 2025-05-29T00:00:00.000Z [neutral] Risk: low
  Acadia Pharmaceuticals Inc. filed an 8-K on May 29, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain specific
• Acadia Pharmaceuticals Inc. Files 8-K — 8-K · 2025-05-20T00:00:00.000Z [neutral] Risk: low
  On May 15, 2025, Acadia Pharmaceuticals Inc. entered into a material definitive agreement. The company also reported on other events on this date. The filing wa
• Acadia Pharmaceuticals Files Q1 2025 10-Q — 10-Q · 2025-05-08T00:00:00.000Z [neutral] Risk: medium
  Acadia Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The filing details their financial performance and business operations. Key fin
• Acadia Pharmaceuticals Files 8-K on Financials — 8-K · 2025-05-07T00:00:00.000Z [neutral] Risk: low
  On May 7, 2025, Acadia Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
• ACADIA Pharma Executive Compensation Details Revealed — DEF 14A · 2025-04-25T00:00:00.000Z [neutral] Risk: low
  ACADIA Pharmaceuticals Inc. filed its DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing inclu
• Acadia Pharmaceuticals Files 8-K Report — 8-K · 2025-04-16T00:00:00.000Z [neutral] Risk: low
  On April 15, 2025, Acadia Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns amendments to its Articles of Incorporation or Bylaws and the
• Acadia Pharmaceuticals Files 2024 10-K — 10-K · 2025-02-27T00:00:00.000Z [neutral] Risk: medium
  Acadia Pharmaceuticals Inc. filed its 2024 10-K on February 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in San Diego, CA
• Acadia Pharmaceuticals Files 8-K on Financials — 8-K · 2025-02-26T00:00:00.000Z [neutral] Risk: low
  Acadia Pharmaceuticals Inc. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition. The filing includes financial sta
• Acadia Pharmaceuticals Completes Cerimon Therapeutics Acquisition — 8-K · 2024-12-11T00:00:00.000Z [bullish] Risk: medium
  On December 11, 2024, ACADIA Pharmaceuticals Inc. reported the completion of its acquisition of all outstanding shares of Cerimon Therapeutics GmbH. The transac
• Acadia Pharma Names New Directors, Updates Exec Pay — 8-K · 2024-11-20T00:00:00.000Z [neutral] Risk: low
  Acadia Pharmaceuticals Inc. announced on November 18, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• ACADIA Pharmaceuticals Files Q3 2024 10-Q — 10-Q · 2024-11-07T00:00:00.000Z [neutral] Risk: medium
  ACADIA Pharmaceuticals Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its business
• ACADIA Pharmaceuticals Files 8-K on Financials — 8-K · 2024-11-06T00:00:00.000Z [neutral] Risk: low
  On November 6, 2024, ACADIA Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations,
• Acadia Pharmaceuticals Appoints New Directors, Updates Executive Contracts — 8-K · 2024-09-23T00:00:00.000Z [neutral] Risk: low
  Acadia Pharmaceuticals Inc. announced on September 17, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two
• ACADIA Pharmaceuticals Q2 2024 Update — 10-Q · 2024-08-07T00:00:00.000Z [neutral] Risk: medium
  ACADIA Pharmaceuticals Inc. reported its financial results for the quarter ended June 30, 2024. The company's filing details its financial position and operatio
• ACADIA Pharmaceuticals Files 8-K on Financials — 8-K · 2024-08-06T00:00:00.000Z [neutral] Risk: low
  On August 6, 2024, ACADIA Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, a
• Acadia Pharma Appoints New CMO, Elects Director — 8-K · 2024-05-29T00:00:00.000Z [neutral] Risk: low
  Acadia Pharmaceuticals Inc. announced on May 29, 2024, the appointment of Dr. Anya Schiess as Chief Medical Officer and the election of Dr. David E. Michelson t
• ACADIA Pharmaceuticals Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-09T00:00:00.000Z [neutral] Risk: medium
  ACADIA PHARMACEUTICALS INC (ACAD) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. ACADIA Pharmaceuticals Inc. filed a 10-Q report for the period en
• Acadia Pharmaceuticals Files 8-K on Financials — 8-K · 2024-05-08T00:00:00.000Z [neutral] Risk: low
  Acadia Pharmaceuticals Inc. filed an 8-K on May 08, 2024, reporting on its results of operations and financial condition. The filing includes financial statemen
• ACADIA Pharmaceuticals Inc. Files Definitive Proxy Statement — DEF 14A · 2024-04-26T00:00:00.000Z [neutral] Risk: low
  ACADIA PHARMACEUTICALS INC (ACAD) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. The filing is a Definitive Proxy Statement (DEF 14A) for ACA
• Acadia Pharmaceuticals Files 8-K Report — 8-K · 2024-03-11T00:00:00.000Z [neutral] Risk: low
  On March 11, 2024, Acadia Pharmaceuticals Inc. filed an 8-K report. The filing primarily serves as a notification of other events, with no specific material eve
• ACADIA Pharmaceuticals Inc. Files 2023 Annual Report (10-K) — 10-K · 2024-02-28T00:00:00.000Z [neutral] Risk: medium
  ACADIA PHARMACEUTICALS INC (ACAD) filed a Annual Report (10-K) with the SEC on February 28, 2024. ACADIA Pharmaceuticals Inc. filed its 10-K report for the fisc
• Acadia Pharma Files 8-K on Financial Results and Exhibits — 8-K · 2024-02-27T00:00:00.000Z [neutral] Risk: low
  Acadia Pharmaceuticals Inc. filed an 8-K on February 27, 2024, to report on its "Results of Operations and Financial Condition" and "Financial Statements and Ex
• SC 13G Filing — SC 13G · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• FMR LLC & Abigail Johnson Trim ACADIA PHARMACEUTICALS Stake to 3.207% — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in ACADIA PHARMACEUTICALS INC. As of February
• Acadia Pharma Reports Executive Compensation Changes — 8-K · 2024-01-31T00:00:00.000Z [neutral]
  Acadia Pharmaceuticals Inc. filed an 8-K on January 31, 2024, reporting an event that occurred on January 30, 2024, related to changes in its executive compensa
• BlackRock Amends Passive Stake in Acadia Pharmaceuticals — SC 13G/A · 2024-01-26T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating its ownership of ACADIA PHARMACEUTICALS INC common stock as of December 31, 2023. This